Mirati 516-005 "SAPPHIRE"

Lung Non Small Cell - SAPPHIRE

Mirati 516-005 "SAPPHIRE"

Objective

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy

Principal Investigator(s)
Thomas Lowe, MD

Clinical Trial Categories

  • UCLA Trio Clinical Trials